Partnerships Archives

News and Trends 16 Sep 2022

Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women

Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained countries. Breast cancer is the most diagnosed cancer and the cause of the most cancer-related deaths in women. Similarly, cervical cancer is the fourth most […]

September 16, 2022 - 3 minutesmins - By Jim Cornall

Prothena, Parkinsons Disease, neurons, neurological diseases

News and Trends 15 Sep 2022

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Collaboration to explore gene therapy products for neurodegenerative disorders

Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

September 12, 2022 - 5 minutesmins - By Jim Cornall

CRISPR, CRISPR-Cas9, genome-editing, gene therapy

News and Trends 8 Sep 2022

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […]

September 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

OncoBone signs deals with three partners to work on bone metastases

OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Lonza and Touchlight collaboration will expands customer’s access to DNA

Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […]

September 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

Synaffix and Emergence in $360M technology platform deal to develop ADCs

Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […]

September 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […]

September 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Study of injection to treat schizophrenia to begin after $3M payment received

A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […]

September 1, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Sep 2022

License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East

A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […]

September 1, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Partnerships

Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Collaboration to explore gene therapy products for neurodegenerative disorders

Astellas, Seagen and Merck give details on urothelial cancer treatment

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

OncoBone signs deals with three partners to work on bone metastases

Lonza and Touchlight collaboration will expands customer’s access to DNA

Synaffix and Emergence in $360M technology platform deal to develop ADCs

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Study of injection to treat schizophrenia to begin after $3M payment received

License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!